SEC Comment Letter 0000000000-23-012446 to Armata Pharmaceuticals, Inc. (ARMP)

Armata Pharmaceuticals, Inc.
Date: Nov. 13, 2023 · CIK: 0000921114 · Accession: 0000000000-23-012446

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37544

Date

November 13, 2023

Author

Division of Corporation Finance

Form

UPLOAD

Company

Armata Pharmaceuticals, Inc.

Letter

United States securities and exchange commission logo November 13, 2023 Richard Rychlik VP, Corporate Controller Armata Pharmaceuticals, Inc. 5005 McConnell Avenue Los Angeles, CA 90066 Re:Armata Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2022 Form 10-Q for the quarterly period ended June 30, 2023 File No. 001-37544 Dear Richard Rychlik: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation Finance
Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
November 13, 2023
Richard Rychlik
VP, Corporate Controller
Armata Pharmaceuticals, Inc.
5005 McConnell Avenue
Los Angeles, CA 90066
Re:Armata Pharmaceuticals, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Form 10-Q for the quarterly period ended June 30, 2023
File No. 001-37544
Dear Richard Rychlik:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io